Obefazimod’s strong Phase 3 induction data positions Abivax as a leading UC contender. Check out why I initated my coverage ...

Abviax's Obefazimod shows strong potential in ulcerative colitis treatment. Upcoming phase 3 trial data in Q3 2025 is a key ...

Besides Rinvoq, Xeljanz and Olumiant are also awaiting FDA decisions on their atopic dermatitis filings. ... Gal suggested five years would be a reasonable estimate for a similar Rinvoq trial.

But since Olumiant and Rinvoq "share mechanisms of action with Xeljanz, FDA considers that these medicines may have similar risks as seen in the Xeljanz safety trial," the agency said.

Although they were not involved in the trials, two other drugs in the Janus kinase (JAK) inhibitors class, Olumiant (baricitinib) and Rinvoq (upadacitinib), are included in the warning requirement.

Rinvoq beats the industry leader in a late-stage head-to-head study. Rinvoq achieved superiority compared to Dupixent for the trial's primary endpoint, meaning the former drug reported a higher ...

If Rinvoq manages to cross the FDA’s finish line in ulcerative colitis, it could end up dominating the space over the likes of its competitors, such as Xeljanz and Gilead’s filgotinib ...

This is a JAK inhibitor, Pfizer's Xeljanz saw an increased risk of serious heart-related issues and cancer in their clinical trial.As you said, AbbVie is really counting on Rinvoq to make up for ...

AbbVie's rheumatoid arthritis drug Rinvoq and Pfizer's Xeljanz are now recommended for use only in patients, who have had inadequate response or intolerance to one or more TNF blockers, which are ...

The warnings stem from the FDA's review of Pfizer's arthritis drug Xeljanz after initial results from a February trial showed an increased risk of serious heart-related problems and cancer ...

AbbVie announced that its drug therapy upadacitinib (also known as RINVOQ®) is entering Phase 3 clinical trial for treatment of lupus. RINVOQ is already approved for the treatment of other autoimmune ...

AbbVie has revealed positive data from a post-hoc analysis of the Phase III Measure Up 1 and Measure Up 2 clinical trials of RINVOQ (upadacitinib) in treating moderate-to-severe atopic dermatitis ...